基本信息
浏览量:148
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
个人简介
I’ve been Professor of Surgery for over 25 years and Consultant Surgeon for over 30 years, with wide clinical experience in Surgical Oncology and over 35 years specialising in breast cancer, both clinical and research. Expertise includes treating patients from prevention through to advanced breast cancer. I’m an acknowledged expert in both therapeutics and diagnostics.
Over a number of years, I’ve worked with pharmaceutical companies as clinical trials investigator, advisory board member, expert advisor on regulatory drug submissions, and patent litigation. Regarding clinical trials, I’ve been Chief Investigator (CI) on a large number of Phase 2 and 3 multi-centre studies (national & international). This has included several pre-surgical randomised trials, assessing pharmacodynamic and pharmacokinetic aspects of new drugs; this role has been in both company-sponsored and investigator-initiated trials. I’ve also advised biotechnology companies on their new drugs.
Over the course of 35 years, I’ve founded two biotech companies, along with developing, and continuing to lead, a research programme on what is now called ‘liquid biopsies’. I developed EarlyCDT-Lung (also called Nodify CDT Lung), the first blood test for the early detection of (lung) cancer measuring a panel of seven autoantibodies. A randomised controlled trial (ECLS) of over 12,000 smokers and ex-smokers reported that participants randomised to the EarlyCDT-Lung test had a 36% reduction in diagnosis of late-stage lung cancers.
One of my current projects includes leading an audit of breast conserving surgery for Ductal Carcinoma in Situ (DCIS) diagnosed within the UK NHS Breast Screening Programme.
Over a number of years, I’ve worked with pharmaceutical companies as clinical trials investigator, advisory board member, expert advisor on regulatory drug submissions, and patent litigation. Regarding clinical trials, I’ve been Chief Investigator (CI) on a large number of Phase 2 and 3 multi-centre studies (national & international). This has included several pre-surgical randomised trials, assessing pharmacodynamic and pharmacokinetic aspects of new drugs; this role has been in both company-sponsored and investigator-initiated trials. I’ve also advised biotechnology companies on their new drugs.
Over the course of 35 years, I’ve founded two biotech companies, along with developing, and continuing to lead, a research programme on what is now called ‘liquid biopsies’. I developed EarlyCDT-Lung (also called Nodify CDT Lung), the first blood test for the early detection of (lung) cancer measuring a panel of seven autoantibodies. A randomised controlled trial (ECLS) of over 12,000 smokers and ex-smokers reported that participants randomised to the EarlyCDT-Lung test had a 36% reduction in diagnosis of late-stage lung cancers.
One of my current projects includes leading an audit of breast conserving surgery for Ductal Carcinoma in Situ (DCIS) diagnosed within the UK NHS Breast Screening Programme.
研究兴趣
论文共 446 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Mark Sibbering,Veronica Rogers,Denise Stafford, Lisa Rose,Karen Ives-Smith, Kevin Clifton, Iman Azmy,Thilan Bartholomeuz,John Robertson
European Journal of Surgical Oncology (2024)
European Journal of Surgical Oncology (2024)
Lisa Rose,Denise Stafford,Veronica Rogers,Karen Ives-Smith, Kevin Clifton, Iman Azmy,Thilan Bartholomeuz,John Robertson,Mark Sibbering
European Journal of Surgical Oncology (2024)
Cancer Researchno. 9_Supplement (2024): PS09-08
medrxiv(2024)
CANCER RESEARCHno. 5 (2023)
Cancer Researchno. 5_Supplement (2023): PD10-08
Cancer Researchno. 5_Supplement (2023): PD10-07
CANCER RESEARCHno. 5 (2023)
加载更多
作者统计
#Papers: 446
#Citation: 24805
H-Index: 85
G-Index: 148
Sociability: 8
Diversity: 3
Activity: 51
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn